| Subject: | FDA Issues Warning Letter to Ranbaxy Laboratories, Ltd. |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 17 Sep 2008 - 12:00 pm |
| The U.S. Food and Drug Administration (FDA) has issued two Warning Letters to Ranbaxy Laboratories, Ltd., an India-based manufacturer of generic drugs, some for the U.S. market. The Warning Letters address the manufacturing conditions at two different Ranbaxy plants in Dewas and Paonta Sahib India. FDA inspections have shown extensive deviations from U.S. current Good Manufacturing Practice (cGMP) requirements. Additionally, the FDA has issued an Import Alert, which the FDA can use to bar... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
